Nadoxolol

Nadoxolol is a non-selective beta-adrenergic receptor blocker investigated for its potential use in treating hypertension and other cardiovascular conditions. It is characterized by a long duration of action and is administered orally. Nadoxolol distinguishes itself from some other beta-blockers with its hydrophilic properties, which limit its passage across the blood-brain barrier, potentially reducing central nervous system side effects. It functions by competitively blocking the effects of catecholamines like adrenaline (epinephrine) and noradrenaline (norepinephrine) on beta-adrenergic receptors in the heart and blood vessels, leading to a decrease in heart rate, blood pressure, and myocardial contractility. This mechanism of action can be beneficial in managing angina pectoris, arrhythmias, and hypertension. However, like other beta-blockers, nadoxolol can have contraindications, including asthma, chronic obstructive pulmonary disease (COPD), and certain heart conditions. It also may interact with other medications. Clinical use of nadoxolol has been limited, and it is not widely available in all countries. Further research may be required to fully elucidate its therapeutic potential and safety profile.